Trial Profile
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Treatment-Naïve and Treatment-Experienced, Non-Cirrhotic Asian Adults With Subgenotype 1b Chronic Hepatitis C Virus (HCV) Infection
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 Dec 2018
Price :
$35
*
At a glance
- Drugs Dasabuvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary)
- Indications Hepatitis C
- Focus Registrational; Therapeutic Use
- Acronyms ONYX-I
- Sponsors AbbVie
- 13 Nov 2018 Results presented at The Liver Meeting 2018: 69th Annual Meeting of the American Association for the Study of Liver Diseases
- 16 Jun 2018 Results assessing the Pharmacokinetics of Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir in Healthy and HCV GT1b-Infected Chinese, Korean and Taiwanese Patients from NCT02534870, NCT02517515, NCT02517528 and one more study, published in the European Journal of Drug Metabolism and Pharmacokinetics
- 10 Jul 2017 Status changed from active, no longer recruiting to completed.